Table 41Results of the Univariate Sensitivity Analysis Regarding Starting Age

Source for UtilitiesResult
Starting age = 36 years (base case)If λ < $118,242, glatiramer acetate is cost-effective treatment.
If $118,242 < λ < $425,655, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment.
If $425,655 < λ < $872,972, dimethyl fumarate is a cost-effective treatment.
If λ > $872,972, natalizumab is a cost-effective treatment.
Starting age = 20 yearsIf λ < $116,736, glatiramer acetate is costa cost-effective treatment.
If $116,736 < λ < $424,763, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment.
If $424,763 < λ < $867,355, dimethyl fumarate is a cost-effective treatment.
If λ > $867,355, natalizumab is a cost-effective treatment.
Starting age = 50 yearsIf λ < $124,133, glatiramer acetate is cost-effective treatment.
If $124,133 < λ < $428,976, interferon beta-1b 250 mcg (Extavia) is a cost-effective treatment.
If $428,976 < λ < $894,322, dimethyl fumarate is a cost-effective treatment.
If λ > $894,322, natalizumab is cost-effective treatment.

mcg = microgram.

From: 4, RESULTS

Cover of Management of Relapsing-Remitting Multiple Sclerosis
Management of Relapsing-Remitting Multiple Sclerosis [Internet].
CADTH Therapeutic Review, No. 1.2.
Copyright © CADTH March 2013.

You are permitted to make copies of this document for non-commercial purposes provided it is not modified when reproduced and appropriate credit is given to CADTH. You may not otherwise copy, modify, translate, post on a website, store electronically, republish or redistribute any material from the website in any form or by any means without the prior written permission of CADTH.

Please contact CADTH’s Vice-President of Corporate Services at ac.htdac@secivresetaroproc with any inquiries about this notice or other legal matters relating to CADTH’s services.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.